The transition from first-line to second-line therapy in multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Effective management of multiple sclerosis (MS) activity, especially early on, is vital to prevent long-term disability.
• Current disease-modifying drugs (DMDs) are categorized as first- or second-line, but real-world guidelines for switching therapies are lacking.
• The landscape of MS treatment strategies, including first- and second-line approaches, is continually evolving.

Purpose of the Study:

• To provide evidence-based guidance on optimizing multiple sclerosis (MS) treatment by switching from first-line to second-line therapies.
• To outline decision-making criteria for initiating treatment transitions in MS patients.
• To summarize data supporting treatment optimization based on response, tolerability, safety, and adherence.

Main Methods:

• Review and synthesis of existing data on switching disease-modifying drugs (DMDs) in multiple sclerosis (MS).
• Analysis of reasons for treatment switching, including inadequate response, tolerability, safety concerns, and adherence issues.
• Examination of different therapeutic strategies, such as intra-class switching and escalation to more potent agents.

Main Results:

• Switching from first-line to second-line therapy in MS is motivated by inadequate response, tolerability, safety, or adherence.
• Intra-class switching (e.g., interferon beta to glatiramer acetate) or switching to oral medications (dimethylfumarate, teriflunomide) can be options for tolerability issues.
• Escalation to more potent therapies (natalizumab, fingolimod, alemtuzumab) is suggested for treatment failure, though with potential risk-benefit considerations.

Conclusions:

• Treatment decisions for switching MS therapies must be individualized, considering patient-specific factors and risk profiles.
• While some drugs have varying approval statuses across regions (e.g., fingolimod), direct efficacy comparisons among second-line options are limited.
• A personalized approach is essential for optimizing MS treatment outcomes when transitioning between therapy lines.